scholarly journals Impact of NPS MedicineWise general practitioner education programs and Choosing Wisely Australia recommendations on prescribing of proton pump inhibitors in Australia

2020 ◽  
Author(s):  
Jianyun Wu ◽  
Scott Dickinson ◽  
Zain Elgebaly ◽  
Suzanne Gaye Blogg ◽  
Aine Heaney ◽  
...  
Keyword(s):  
General Practitioners ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Causal Relation ◽  
High Standard ◽  
Choosing Wisely ◽  
Royal Australian College ◽  
Low Strength ◽  
Practitioner Education ◽  
The Impact

Abstract Background: This study evaluated the impact of multifaceted NPS MedicineWise programs conducted in 2009 and 2015 that targeted general practitioners (GPs) to reduce unnecessary prescribing of proton pump inhibitors (PPIs). Methods: Time series analyses was conducted of the dispensing rates of concessional PPI scripts between January 2006 and June 2016 using the Pharmaceutical Benefits Scheme (PBS) and Medicare Benefits Schedule (MBS) databases in Australia. Participants were GPs with dispensed PPI prescriptions to concessional patients between January 2006 and June 2016. The interventions were national NPS MedicineWise PPI educational programs in 2009 and 2015 delivered to all practising GPs in Australia. The 2015 intervention coincided with the release of Choosing Wisely Australia recommendations from the Royal Australian College of General Practitioners (RACGP). Outcome measures included monthly dispensing rates of high/standard and low strength PPIs prescribed by GPs among concessional patients in Australia. Results : Following the 2009 NPS MedicineWise program we observed a 6.7% reduction in the expected dispensing rate of standard strength PPIs among concessional patients between January 2006 and March 2015, and a total 8.6% reduction by June 2016 following the launch of the 2015 program. We observed a significant increase of 5.6% in the dispensing rate of low strength PPIs among concessional patients between April 2009 and March 2015, and no significant change in trend following the 2015 program. Conclusions: The NPS MedicineWise programs were associated with reductions in the dispensing rate of high/standard strength PPIs and with an increase in the dispensing rate of low-strength PPIs by June 2016 although a causal relation was not confirmed. Although the rate of high/standard strength PPI prescribing is declining, these formulations still constitute the majority of PPIs used in Australia. Regular interventions to sustain and improve PPI management by GPs may be warranted.

scholarly journals Impact of NPS MedicineWise general practitioner education programs and Choosing Wisely Australia recommendations on prescribing of proton pump inhibitors in Australia

2019 ◽  
Author(s):  
Jianyun Wu ◽  
Scott Dickinson ◽  
Zain Elgebaly ◽  
Suzanne Gaye Blogg ◽  
Aine Heaney ◽  
...  
Keyword(s):  
General Practitioners ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Causal Relation ◽  
Choosing Wisely ◽  
Royal Australian College ◽  
Time Series Analyses ◽  
Low Strength ◽  
Practitioner Education ◽  
The Impact

Abstract Background: This study evaluated the impact of multifaceted NPS MedicineWise programs conducted in 2009 and 2015 that targeted general practitioners (GPs) to reduce unnecessary prescribing of proton pump inhibitors (PPIs). Methods: Time series analyses was conducted of the dispensing rates of concessional PPI scripts between January 2006 and June 2016 using the Pharmaceutical Benefits Scheme (PBS) and Medicare Benefits Schedule (MBS) databases in Australia. Participants were GPs with dispensed PPI prescriptions to concessional patients between January 2006 and June 2016. The interventions were national NPS MedicineWise PPI educational programs in 2009 and 2015 delivered to all practising GPs in Australia. The 2015 intervention coincided with the release of Choosing Wisely Australia recommendations from the Royal Australian College of General Practitioners (RACGP). Outcome measures included monthly dispensing rates of standard and low strength PPIs prescribed by GPs among concessional patients in Australia. Results : Following the 2009 NPS MedicineWise program we observed a 6.7% reduction in the expected dispensing rate of standard strength PPIs among concessional patients between January 2006 and March 2015, and a total 8.6% reduction by June 2016 following the launch of the 2015 program. We observed a significant increase of 5.6% in the dispensing rate of low strength PPIs among concessional patients between April 2009 and March 2015, and no significant change in trend following the 2015 program. Conclusions: The NPS MedicineWise programs were associated with reductions in the dispensing rate of standard strength PPIs, and with an increase in the dispensing rate of low-strength PPIs by June 2016 although a causal relation was not confirmed. Although the rate of standard strength PPI prescribing is declining, these formulations still constitute the majority of PPIs used in Australia. Regular interventions to sustain and improve PPI management by GPs may be warranted.

scholarly journals Impact of NPS MedicineWise general practitioner education programs and Choosing Wisely Australia recommendations on prescribing of proton pump inhibitors in Australia

2020 ◽  
Author(s):  
Jianyun Wu ◽  
Scott Dickinson ◽  
Zain Elgebaly ◽  
Suzanne Gaye Blogg ◽  
Aine Heaney ◽  
...  
Keyword(s):  
General Practitioners ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Causal Relation ◽  
Choosing Wisely ◽  
Royal Australian College ◽  
Time Series Analyses ◽  
Low Strength ◽  
Practitioner Education ◽  
The Impact

Abstract Background: This study evaluated the impact of multifaceted NPS MedicineWise programs conducted in 2009 and 2015 that targeted general practitioners (GPs) to reduce unnecessary prescribing of proton pump inhibitors (PPIs). Methods: Time series analyses was conducted of the dispensing rates of concessional PPI scripts between January 2006 and June 2016 using the Pharmaceutical Benefits Scheme (PBS) and Medicare Benefits Schedule (MBS) databases in Australia. Participants were GPs with dispensed PPI prescriptions to concessional patients between January 2006 and June 2016. The interventions were national NPS MedicineWise PPI educational programs in 2009 and 2015 delivered to all practising GPs in Australia. The 2015 intervention coincided with the release of Choosing Wisely Australia recommendations from the Royal Australian College of General Practitioners (RACGP). Outcome measures included monthly dispensing rates of standard and low strength PPIs prescribed by GPs among concessional patients in Australia. Results : Following the 2009 NPS MedicineWise program we observed a 6.7% reduction in the expected dispensing rate of standard strength PPIs among concessional patients between January 2006 and March 2015, and a total 8.6% reduction by June 2016 following the launch of the 2015 program. We observed a significant increase of 5.6% in the dispensing rate of low strength PPIs among concessional patients between April 2009 and March 2015, and no significant change in trend following the 2015 program. Conclusions: The NPS MedicineWise programs were associated with reductions in the dispensing rate of standard strength PPIs and with an increase in the dispensing rate of low-strength PPIs by June 2016 although a causal relation was not confirmed. Although the rate of standard strength PPI prescribing is declining, these formulations still constitute the majority of PPIs used in Australia. Regular interventions to sustain and improve PPI management by GPs may be warranted.

scholarly journals Impact of NPS MedicineWise General Practitioner education programs and Choosing Wisely Australia recommendations on prescribing of Proton Pump Inhibitors in Australia

2019 ◽  
Author(s):  
Jianyun Wu ◽  
Scott Dickinson ◽  
Zain Elgebaly ◽  
Suzanne Gaye Blogg ◽  
Aine Heaney ◽  
...  
Keyword(s):  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
High Strength ◽  
Choosing Wisely ◽  
Education Programs ◽  
Time Series Analyses ◽  
Low Strength ◽  
Practitioner Education ◽  
The Impact ◽  
Pharmaceutical Benefits Scheme

Abstract Background This study evaluated the impact of multifaceted NPS MedicineWise programs conducted in 2009 and 2015 that targeted general practitioners (GPs) to reduce unnecessary prescribing of proton pump inhibitors (PPIs). Methods Time series analyses of the dispensing rates of concessional PPI scripts between January 2006 and June 2016 using the Pharmaceutical Benefits Scheme (PBS) and Medicare Benefits Schedule (MBS) databases in Australia. Participants were GPs with dispensed PPI prescriptions to concessional patients between January 2006 and June 2016. The interventions were National NPS MedicineWise PPI educational programs in 2009 and 2015 delivered to all practising GPs in Australia. The 2015 intervention coincided with the release of Choosing Wisely Australia recommendations from the RACGP. Outcome measures included monthly dispensing rates of standard and low strength PPIs prescribed by GPs among concessional patients in Australia. Results Following the 2009 NPS MedicineWise program we observed a 6.7% reduction in the expected dispensing rate of standard strength PPIs among concessional patients between January 2006 and March 2015, and a total 8.6% reduction by June 2016 following the launch of the 2015 program. We observed a significant increase of 5.6% in the expected dispensing rate of low strength PPIs among concessional patients between April 2009 and March 2015, and no significant change in trend following the 2015 program. Conclusions The NPS MedicineWise programs were associated with reductions in the dispensing rate of standard strength PPIs, and with an increase in the dispensing rate of low-strength PPIs by June 2016. Although the rate of high-strength PPI prescribing is declining, these formulations still constitute the majority of PPI use in Australia. Regular interventions to sustain and improve PPI management by GPs may be warranted.

scholarly journals The impact of proton pump inhibitors on the pharmacokinetics of voriconazole in vitro and in vivo

2018 ◽  
Vol 108 ◽  
pp. 60-64 ◽  
Author(s):  
Miao Yan ◽  
Zhu-feng Wu ◽  
Dan Tang ◽  
Feng Wang ◽  
Yi-wen Xiao ◽  
...  
Keyword(s):  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
The Impact

Prescribing of proton-pump inhibitors: auditing the management and reasons for prescribing in Danish general practice

2019 ◽  
Vol 36 (6) ◽  
pp. 758-764
Author(s):  
Dorte E Jarbøl ◽  
Jesper Lykkegaard ◽  
Jane M Hansen ◽  
Anders Munck ◽  
Peter F Haastrup
Keyword(s):  
General Practitioner ◽  
Proton Pump Inhibitor ◽  
General Practitioners ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Patient Characteristics ◽  
Clinical Settings ◽  
Staff Members ◽  
Term Basis

Abstract Background Prescribing of proton-pump inhibitors has substantially increased. Information from clinical settings is warranted to gain insight into reasons for prescribing. Aim To investigate Danish General Practitioners’ management and reasons for prescribing of proton-pump inhibitors and to identify areas for quality improvement. Methods All general practitioners in the Region of Southern Denmark and their staff were invited to participate in a 4-week audit on all contacts with patients prescribed proton-pump inhibitors. For each contact, patient characteristics, treatment duration, dose and causes of treatment, previous gastroscopy, Helicobacter pylori test, and decision about future treatment were recorded. Results A total of 51 general practitioners and 47 staff members sampled information about 1101 and 741 patients, respectively. Proton-pump inhibitors had been taken for more than 2 years in 58% of the cases, and 64% of the patients used it daily. Treatment was based on an appropriate reason in three of the four patients, most often due to acid-related symptoms. No gastroscopy had been performed in 46% of the patients, and one of four had had a consultation with the general practitioner regarding proton-pump inhibitor within the last year. Conclusion Most patients treated with proton-pump inhibitors are treated daily, on a long-term basis, and due to symptoms. Few consultations led to alterations in treatment, and only 25% of patients had a consultation regarding proton-pump inhibitor treatment with their general practitioner within the last year. Substantial variability between general practitioners with regard to management was detected.

Proton Pump Inhibitors and Dabigatran Therapy: Impact on Gastric Bleeding and Dabigatran Plasma Levels

2019 ◽  
Vol 45 (08) ◽  
pp. 846-850 ◽  
Author(s):  
Tomáš Bolek ◽  
Matej Samoš ◽  
Ingrid Škorňová ◽  
Peter Galajda ◽  
Ján Staško ◽  
...  
Keyword(s):  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Plasma Levels ◽  
Thrombin Inhibitor ◽  
Gi Bleeding ◽  
Gastric Bleeding ◽  
Increased Risk ◽  
The Impact ◽  
Dabigatran Therapy

AbstractDabigatran etexilate, a direct thrombin inhibitor, is now frequently used for long-term pharmacological prevention of stroke or systemic embolism in patients with atrial fibrillation. However, such long-term dabigatran therapy (DT) significantly increases the risk of upper gastrointestinal (GI) bleeding. This increased risk of gastric bleeds might be reduced with gastroprotective agents, such as proton pump inhibitors (PPIs). PPIs coadministrated with dabigatran reduce the risk of upper GI bleeding in patients on long-term oral DT. Nevertheless, there is heated discussion regarding interactions between PPI and dabigatran that lead to decreases in dabigatran plasma levels. This article reviews up to date data about the risk of gastric bleeding on dabigatran, the impact of PPI on the reduction of gastric bleeding, and the interaction between PPI and dabigatran leading to decreased dabigatran plasma levels.

Sign in / Sign up

Export Citation Format

Share Document